A marriage of clinical trial results and imaging findings with icosapent ethyl

Results of the EVAPORATE trial

10' education - Sep. 21, 2020 - Fabrice Martens, MD, PhD, prof. Matthew Budoff, MD and prof. Gabriel Steg MD

Video navigation menu

Results of the EVAPORATE study 00:54
Start of the discussion: mechanism of action, inertness of placebo 04:42
Discussion: low attenuation plaque volume as primary end point, heterogeneity of treatment effect, calcified plaques 08:50
Discussion: likely multifactorial effects, stenosis 14:26

Educational information

The educational objective of this video is to provide cardiovascular physicians with the latest findings and interpretations of studies.

Faculty

- Fabrice Martens, MD, PhD is a cardiologist at the Deventer Hospital, The Netherlands

- Ph. Gabriel Steg, MD is a cardiologist in the Hôpital Bichat, Paris, France. He is also Professor at the National Heart and Lung Institute, Imperial College, London, UK.

- Matthew J Budoff, MD is investigator at Lundquist Institute and Professor of Medicine, David Geffen School of Medicine at UCLA and Program Director and Director of Cardiac CT, Division of Cardiology, Harbor-UCLA Medical Center, Los Angeles, CA, USA.

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

Funding

This educational program was sponsored by unrestricted educational grants from Amarin.

Read our summary of the EVAPORATE study Read our summary of the REDUCE-IT trial

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.